Intellia Therapeutics NTLA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -636.6%+551pp | -651.7%+271pp | -832.2%+363pp | -968.7%+126pp | -1,187.4%-238pp | |
| Net margin | -597%+557pp | -609.9%+287pp | -774.9%+386pp | -908.5%+154pp | -1,154.1%-264pp | |
| EBITDA margin | -622.2%+543pp | -637.2%+268pp | -814.8%+357pp | -949.5%+124pp | -1,164.8%-233pp | |
| Free cash flow margin | -550.2%+286pp | -585%+27.8pp | -717.3%+89.5pp | -798%+1.1pp | -836.4%-69.6pp | |
| Returns | ||||||
| Return on equity | -56.3%+1.6pp | -53.5%+0.5pp | -52.1%+0.1pp | -57%-7.9pp | -57.9%-14.3pp | |
| Return on assets | -45.2%+1.6pp | -40.6%+1.1pp | -42.5%+0.7pp | -45.9%-5.5pp | -46.8%-10.6pp | |
| Return on invested capital | -62.8%-0.9pp | -58.7%-0.4pp | -60%-4.3pp | -63.7%-11.3pp | -61.9%-10.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 6.1×+1.2× | 5.1×-0.7× | 6.2×-0.5× | 5.2×-2.0× | 4.9×-4.1× | |
| Quick ratio | 6.1×+1.2× | 5.1×-0.7× | 6.2×-0.5× | 5.2×-2.0× | 4.9×-4.1× | |
| Cash ratio | 1.8×+0.6× | 1.5×-0.2× | 2.1×+0.9× | 1.6×+0.4× | 1.1×-0.6× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×-0.1× | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×-0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $5.24-30.5% | $6.20-29.8% | $6.79-28.7% | $6.90-31.1% | $7.54-30.5% | |
| Valuation | ||||||
| Market capitalization | $1.51B+106% | $1.04B-12.3% | $1.85B-7.0% | $991.29M-53.6% | $736.01M-70.4% | |
| Enterprise value | $1.46B+100% | $979.18M-19.0% | $1.76B-10.9% | $937.71M-55.6% | $728.38M-70.0% | |
| Price / sales | 22.9×+6.8× | 15.4×-5.1× | 32.2×-12.1× | 18.8×-25.9× | 16.2×-29.5× | |
| Price / book | 2.4×+1.5× | 1.6×+0.2× | 2.5×+0.4× | 1.4×-0.8× | 0.9×-1.5× | |
| EV / sales | 22.1×+6.1× | 14.5×-6.4× | 30.6×-13.3× | 17.7×-26.4× | 16×-28.5× | |
| Free cash flow yield | -24%+27.8pp | -38%-8.2pp | -22.3%-4.0pp | -42.6%-24.6pp | -51.8%-35.0pp | |
| Earnings yield | -26.1%+45.4pp | -39.6%+4.1pp | -24%+2.2pp | -48.4%-24.6pp | -71.5%-51.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Intellia Therapeutics's ratios come from?
- Every ratio is computed from Intellia Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.